AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11755283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction (EF) in overlap group
Number of subjects: 2948
Study 11755283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction (EF) < 30%
Number of subjects: 2948
Study 9618751 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological GH treatment (3 IU/m2)
Number of subjects: 48
Study 9618751 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological GH treatment (1 IU/m2 or 2 IU/m2)
Number of subjects: 48
Study 9618751 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 8580491 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8580491 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 2728827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil 0.1 mg.kg‐1
Number of subjects: 44
Study 2728827 — intervention group
Group type: COMPARATOR
Intervention: Control group (thiamylal 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1)
Number of subjects: 44
Study 2728827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil 0.1 mg.kg‐1 (hypertensive patients)
Number of subjects: 44
Study 2728827 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensive patients)
Number of subjects: 44
Study 2728827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HR response)
Number of subjects: 44
Study 848533 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose
Number of subjects: 60
Study 848533 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 60
Study 848533 — intervention group
Group type: COMPARATOR
Intervention: Aminofusin
Number of subjects: 60
Study 848533 — intervention group
Group type: COMPARATOR
Intervention: 10% dextrose
Number of subjects: 60
Study 848533 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine in Hartmann's solution
Number of subjects: 60
Study 11598599 — intervention group
Group type: EXPERIMENTAL
Intervention: Goggles that reduced visible light by 97%
Number of subjects: 409
Study 11598599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no goggles)
Number of subjects: 409
Study 31060104 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet-almond oil (intranasal, 2 drops three times a day for one month)
Number of subjects: 105
Study 31060104 — intervention group
Group type: COMPARATOR
Intervention: Almond oil (intranasal, 2 drops three times a day for one month)
Number of subjects: 105
Study 31060104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% w/v hydroxypropyl methylcellulose solution, intranasal, 2 drops three times a day for one month)
Number of subjects: 105
Study 29559167 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15
Number of subjects: 691
Study 29559167 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 691
Study 29559167 — intervention group
Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 691
Study 27196454 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 80
Study 27196454 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 80
Study 27196454 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 80
Study 24672937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leihong Granule (LG) for 3 months
Number of subjects: 80
Study 24672937 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (Control group)
Number of subjects: 80
Study 22621425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 10
Study 22621425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion after pretreatment with sucralfate
Number of subjects: 10
Study 22621425 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion
Number of subjects: 10
Study 22621425 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate ingestion followed by water
Number of subjects: 10
Study 19823853 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed method (wound closed in two layers over gentamicin impregnated collagen)
Number of subjects: 60
Study 19823853 — intervention group
Group type: COMPARATOR
Intervention: Open method (wound left open post-excision)
Number of subjects: 60
Study 17608873 — intervention group
Group type: EXPERIMENTAL
Intervention: xuezhikang
Number of subjects: 1445
Study 17608873 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1445
Study 15959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status and dietary calcium intake
Number of subjects: 289
Study 15959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight and BMI
Number of subjects: 289
Study 15959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, menopause, and calcium intake
Number of subjects: 289
Study 15959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone area (BA)
Number of subjects: 289
Study 12392348 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 12392348 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 12392348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carbamazepine and lithium
Number of subjects: 0
Study 12392348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of valproate and olanzapine
Number of subjects: 0
Study 10434233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesclim 50
Number of subjects: 24
Study 10434233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesclim 100
Number of subjects: 24
Study 10434233 — intervention group
Group type: COMPARATOR
Intervention: Vivelle 0.05
Number of subjects: 24
Study 7599237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking intervention in addition to ambulation
Number of subjects: 34
Study 7599237 — intervention group
Group type: COMPARATOR
Intervention: Control group (ambulation only)
Number of subjects: 34
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-VC-MTX regimen (Doxorubicin, Cisplatin, Vincristine, Cyclophosphamide, Methotrexate)
Number of subjects: 25
Study 2145702 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide
Number of subjects: 25
Study 2145702 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/Cisplatin
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-OOH-Cyclophosphamide
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine
Number of subjects: 25
Study 2145702 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 25
Study 214866 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained release alprenolol
Number of subjects: 20
Study 214866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31106922 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural skills training (BST)
Number of subjects: 104
Study 31106922 — intervention group
Group type: COMPARATOR
Intervention: Generalised training in behavioural interventions (Control)
Number of subjects: 104
Study 29968684 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises using panflutes for 30 minutes after meals
Number of subjects: 24
Study 29968684 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative education including breathing exercises using incentive spirometers
Number of subjects: 24
Study 26930535 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling
Number of subjects: 120
Study 26930535 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 120
Study 26930535 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 120
Study 25323541 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp‐02 (test formulation)
Number of subjects: 36
Study 25323541 — intervention group
Group type: COMPARATOR
Intervention: Neupogen™ (reference product)
Number of subjects: 36
Study 22703536 — intervention group
Group type: EXPERIMENTAL
Intervention: MxA induction assay
Number of subjects: 125
Study 22703536 — intervention group
Group type: COMPARATOR
Intervention: CPE assay
Number of subjects: 125
Study 20303417 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg, twice daily)
Number of subjects: 82
Study 20303417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17403087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 22418
Study 17403087 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin or unfractionated heparin
Number of subjects: 22418
Study 15830061 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX-A)
Number of subjects: 0
Study 11574336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help with 1 cue call and 3 counseling calls (motivational interviewing)
Number of subjects: 14
Study 11574336 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 14
Study 11574336 — intervention group
Group type: COMPARATOR
Intervention: Self-help intervention with 1 telephone cue call
Number of subjects: 14
Study 9780529 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC-QLQ-C30
Number of subjects: 0
Study 9780529 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 0
Study 9780529 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQoL EQ5D (visual analog scale)
Number of subjects: 0
Study 9780529 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy instrument
Number of subjects: 0
Study 9780529 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic and disease-specific instruments
Number of subjects: 0
Study 8165922 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition
Number of subjects: 109
Study 8165922 — intervention group
Group type: COMPARATOR
Intervention: No-incentive condition
Number of subjects: 109
Study 3047893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamponade (group SB)
Number of subjects: 43
Study 3047893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (group ST)
Number of subjects: 43
Study 30672250 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS at sham acupoints combined with postoperative TEAS at Hegu (LI 4) and Neiguan (PC 6)
Number of subjects: 120
Study 30672250 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS at Hegu (LI 4) and Neiguan (PC 6) combined with postoperative TEAS at sham acupoints
Number of subjects: 120
Study 30672250 — intervention group
Group type: COMPARATOR
Intervention: TEAS at sham acupoints before and after operation
Number of subjects: 120
Study 28552876 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggshell calcium (300 mg/d)
Number of subjects: 54
Study 28552876 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (300 mg/d)
Number of subjects: 54
Study 28552876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no calcium supplementation)
Number of subjects: 54
Study 26039911 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival therapy group (ST, n = 12) received supragingival scaling
Number of subjects: 24
Study 26039911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (IT, n = 12) underwent supra- and subgingival scaling, as well as root planing
Number of subjects: 24
Study 26039911 — intervention group
Group type: COMPARATOR
Intervention: Both groups received professional oral hygiene instructions every month
Number of subjects: 24
Study 23650802 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrium acupuncture
Number of subjects: 287
Study 23650802 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 287
Study 21231790 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-day multi-focus psychosocial residential rehabilitation intervention
Number of subjects: 507
Study 21231790 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 507
Study 19065655 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 rs1799732 CT genotype
Number of subjects: 0
Study 19065655 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 rs1800497 TT genotype
Number of subjects: 0
Study 16861341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic transfusion for primary stroke prevention
Number of subjects: 108
Study 16861341 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 108
Study 16861341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 108
Study 16861341 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 108
Study 16861341 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD results at last testing
Number of subjects: 108
Study 12626983 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg four times daily via gastric tube)
Number of subjects: 84
Study 12626983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times daily via gastric tube)
Number of subjects: 84
Study 10827889 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy guided by a computer or by a therapist
Number of subjects: 0
Study 10827889 — intervention group
Group type: COMPARATOR
Intervention: Relaxation guided by audio-tape
Number of subjects: 0
Study 10827889 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery scenarios (OCD, non-OCD anxiety, neutral)
Number of subjects: 0
Study 10827889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancelling imagery
Number of subjects: 0
Study 9209989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 cc unpreserved lidocaine 1%
Number of subjects: 0
Study 9209989 — intervention group
Group type: COMPARATOR
Intervention: 0.1 cc balanced salt solution (BSS)
Number of subjects: 0
Study 9209989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 cc unpreserved lidocaine 1%
Number of subjects: 0
Study 7895788 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vestibular deafferentation
Number of subjects: 23
Study 7895788 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 23
Study 2459788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy for superficial bladder cancer
Number of subjects: 0
Study 2459788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics for urinary tract infections
Number of subjects: 0
Study 29424805 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (8 mg) with alcohol (1 mL/kg)
Number of subjects: 10
Study 29424805 — intervention group
Group type: COMPARATOR
Intervention: Blonanserin (8 mg) with water
Number of subjects: 10
Study 27768139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 27768139 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study 25015353 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen breathing
Number of subjects: 41
Study 23221984 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-infected women (HCV+)
Number of subjects: 868
Study 23221984 — intervention group
Group type: COMPARATOR
Intervention: HCV-uninfected women (HCV-)
Number of subjects: 868
Study 19712983 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg once daily
Number of subjects: 142
Study 19712983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 17848804 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg ciclesonide for 7 days
Number of subjects: 0
Study 17848804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17848804 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg ciclesonide
Number of subjects: 0
Study 16618294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Number of subjects: 14
Study 16618294 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration into the surgical wound
Number of subjects: 14
Study 12489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of voglibose plus a SU compound (glibenclamide or gliclazide)
Number of subjects: 124
Study 12489066 — intervention group
Group type: COMPARATOR
Intervention: SU drug alone
Number of subjects: 124
Study 9809728 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole-brain radiotherapy (radiotherapy group, 49 patients)
Number of subjects: 95
Study 9809728 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation group, 46 patients)
Number of subjects: 95
Study 7895348 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (TPA) with intravenous heparin
Number of subjects: 41021
Study 7895348 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with subcutaneous heparin
Number of subjects: 41021
Study 7895348 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with intravenous heparin
Number of subjects: 41021
Study 7895348 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase plus TPA with intravenous heparin
Number of subjects: 41021
Study 7895348 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery perfusion (TIMI grade 3) at 90 minutes
Number of subjects: 41021
Study 2793316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular daunomycin
Number of subjects: 0
Study 2793316 — intervention group
Group type: COMPARATOR
Intervention: No intraocular drug (Control)
Number of subjects: 0
Study 330288 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltaren) 100 mg twice daily
Number of subjects: 30
Study 330288 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 30
Study 330288 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltaren)
Number of subjects: 30
Study 330288 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 30
Study 6794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 0
Study 6794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 100 mg
Number of subjects: 0
Study 6794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 50 mg
Number of subjects: 0
Study 6794075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and Doxepin
Number of subjects: 0
Study 30897095 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved infant and young child feeding (IYCF) - 20 g of small-quantity lipid-based nutrient supplement per day from age 6 to 18 months plus complementary feeding counseling
Number of subjects: 1655
Study 30897095 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved water, sanitation, and hygiene (WASH) - ventilated improved pit latrine, handwashing stations, chlorine, liquid soap, and play yard
Number of subjects: 1655
Study 30897095 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH + IYCF
Number of subjects: 1655
Study 30897095 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 1655
Study 29030692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (IVBe)
Number of subjects: 23
Study 29030692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab with subtenon triamcinolone injection (IVBe + STTA)
Number of subjects: 23
Study 26868602 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling combined with technology‐based self‐monitoring for sodium restriction
Number of subjects: 179
Study 26868602 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (received 6 educational modules on the HD diet)
Number of subjects: 179
Study 24981150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel
Number of subjects: 78
Study 24981150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (LD-COC)
Number of subjects: 78
Study 24981150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 24981150 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-COC
Number of subjects: 78
Study 21415280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT)
Number of subjects: 40
Study 21415280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19173688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral state monitor (CSM) group
Number of subjects: 38
Study 19173688 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual clinical criteria)
Number of subjects: 38
Study 19173688 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM group
Number of subjects: 38
Study 19173688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 17262225 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern clinical testing protocol for controlled clinical trials
Number of subjects: 0
Study 17262225 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories of assessment for esthetic evaluation, functional assessment, biological responses to restorative materials
Number of subjects: 0
Study 15990669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity line assessment in standing volunteers and patients with scoliosis
Number of subjects: 86
Study 15990669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity line assessment in both study populations (volunteers and patients)
Number of subjects: 86
Study 11940748 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal feeding (JEN group)
Number of subjects: 110
Study 11940748 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding (GEN group)
Number of subjects: 110
Study 10321139 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance
Number of subjects: 0
Study 10321139 — intervention group
Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 0